Chlorophyll a and novel synthetic derivatives alleviate atopic dermatitis by suppressing Th2 cell differentiation via IL-4 receptor modulation
Clinical Immunology · 2024
DOI: 10.1016/j.clim.2023.109852 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Immunology, 2024. Verfasst von Koon Mook Kang und 15 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Gwangju Institute of Science and Technology, 123 Cheomdangwagi-ro, Buk-gu, Gwangju 61005, Republic of Korea. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Ministry of Trade, Industry and Energy.
Abstract (Originalsprache)
Atopic dermatitis (AD) treatment has largely relied on non-specific broad immunosuppressants despite their long-term toxicities until the approval of dupilumab, which blocks IL-4 signaling to target Th2 cell responses. Here, we report the discovery of compound 4aa, a novel compound derived from the structure of chlorophyll a, and the efficacy of chlorophyll a to alleviate AD symptoms by oral administration in human AD patients. 4aa downregulated GATA3 and IL-4 in differentiating Th2 cells by potently blocking IL-4 receptor dimerization. In the murine model, oral administration of 4aa reduced the clinical severity of symptoms and scratching behavior by 76% and 72%, respectively. Notably, the elevated serum levels of Th2 cytokines reduced to levels similar to those in the normal group after oral administration of 4aa. Additionally, the toxicological studies showed favorable safety profiles and good tolerance. In conclusion, 4aa may be applied for novel therapeutic developments for patients with AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Gwangju Institute of Science and Technology, 123 Cheomdangwagi-ro, Buk-gu, Gwangju 61005, Republic of Korea.
- School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon-si, Gyeonggi-do 16419, Republic of Korea.
- Department of Pharmacy, College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, 55 Hanyangdaehak-ro, Sangnok-gu, Ansan-si, Gyeonggi-do 15588, Republic of Korea.
- R&D Center, Huons co. Ltd., 55 Hanyangdaehak-ro, Sangnok-gu, Ansan-si, Gyeonggi-do 15588, Republic of Korea.
- College of Pharmacy, Dankook University, 119 Dandae-ro, Dongnam-gu, Cheonan-si, Chungcheongnam-do 31116, Republic of Korea.
- Department of Laboratory Medicine, Chonnam National University Hospital, 42 Jebong-ro, Dong-gu, Gwangju 61469, Republic of Korea.
Förderung
- Ministry of Trade, Industry and Energy
Zitieren
APA
Kang, K. M., Han, J. H., Kim, K. S., Kim, E. K., Shin, Y., Park, J. H., Kim, H., Kim, N. Y., Kim, Y. G., Kim, H., Park, H., Kim, Y. M., Kee, S. J., Kim, S. J., Kim, H. S., & Kim, Y. C. (2024). Chlorophyll a and novel synthetic derivatives alleviate atopic dermatitis by suppressing Th2 cell differentiation via IL-4 receptor modulation. Clinical Immunology. https://doi.org/10.1016/j.clim.2023.109852
Vancouver
Kang KM, Han JH, Kim KS, Kim EK, Shin Y, Park JH, et al. Chlorophyll a and novel synthetic derivatives alleviate atopic dermatitis by suppressing Th2 cell differentiation via IL-4 receptor modulation. Clinical Immunology. 2024. doi:10.1016/j.clim.2023.109852
BibTeX
@article{Kang2024,
author = {Kang, Koon Mook and Han, Jung-Hyun and Kim, Kyeong Seok and Kim, Eun Kyung and Shin, Youna and Park, Jae Hyeon and Kim, Hyeon and Kim, Na Yoon and Kim, Yoon Gyoon and Kim, Hyunjun and Park, Hyunjin and Kim, Young-Mi and Kee, Seung-Jung and Kim, Seong-Jin and Kim, Hyung Sik and Kim, Yong-Chul},
title = {Chlorophyll a and novel synthetic derivatives alleviate atopic dermatitis by suppressing Th2 cell differentiation via IL-4 receptor modulation},
journal = {Clinical Immunology},
year = {2024},
doi = {10.1016/j.clim.2023.109852}
}
EUVIMED